NCT03696030: HER2-CAR T Cells in Treating Participants With Brain or Leptomeningeal Metastases

NCT03696030
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 75 Years (Adult, Older Adult)
Location of Metastases: Brain, Leptomeningeal Disease
Additional Notes: 
Exclusions: 
https://ClinicalTrials.gov/show/NCT03696030

Comments are closed.

Up ↑